Literature DB >> 26001509

Interlead anatomic and electrical distance predict outcome in CRT patients.

Giuseppe Stabile1, Antonio D'Onofrio2, Patrizia Pepi3, Antonio De Simone4, Matteo Santamaria5, Salvatore Ivan Caico6, Antonio Rapacciuolo7, Luigi Padeletti8, Domenico Pecora9, Tiziana Giovannini10, Giuseppe Arena11, Alfredo Spotti12, Assunta Iuliano13, Emanuele Bertaglia14, Maurizio Malacrida15, Giovanni Luca Botto16.   

Abstract

BACKGROUND: The implantation strategy appears to play a pivotal role in determining response to cardiac resynchronization therapy (CRT).
OBJECTIVE: The aim of our study was to determine the association between anatomic and electrical interlead distance and clinical outcome after CRT implantation.
METHODS: We included 216 first-time CRT recipients with left bundle branch block and sinus rhythm. On implantation, the electrical interlead distance (EID), defined as the time interval between spontaneous peak R waves detected at the right ventricular (RV) and left ventricular (LV) pacing sites, was measured. The anatomic distance between the RV and LV lead tips was determined on chest radiographs.
RESULTS: The mean EID was 74 ± 41 ms, and the mean horizontal corrected interlead distance (HCID) was 125 ± 73 mm. After 12 months, 87 patients (40%) displayed an improvement in their clinical composite score. The cutoff values that best predicted an improved clinical status were as follows: 84 ms for EID (area under the curve 0.59; confidence interval [CI] 0.52-0.66; P = .026) and 90 mm for HCID (area under the curve 0.62; CI 0.55-0.69; P = .004). On multivariate analysis, only EID >84 ms (hazard ratio 0.36; CI 0.14-0.89; P = .028) and HCID >90 mm (hazard ratio 0.45; CI 0.23-0.90; P = .025) were significantly associated with the composite endpoint of death or cardiovascular hospitalization. In particular, the presence of both conditions (EID <84 ms and HCID <90 mm) was associated with the highest rate of events (log-rank test P = .002).
CONCLUSIONS: The interlead anatomic and electrical distance are strongly and independently associated with patient outcome after CRT implantation. The 2 measures show an additive predictive value. (CRT MORE: Cardiac Resynchronization Therapy Modular Registry; www.clinicaltrials.gov, unique identifier: NCT01573091.)
Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac resynchronization therapy; Heart failure; Interlead distance; Interventricular delay; Left bundle brunch block

Mesh:

Year:  2015        PMID: 26001509     DOI: 10.1016/j.hrthm.2015.05.020

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  4 in total

1.  Maximization of interventricular conduction time by means of quadripolar leads for cardiac resynchronization therapy.

Authors:  Giuseppe Stabile; Valter Bianchi; Francesco Solimene; Assunta Iuliano; Quintino Parisi; Patrizia Pepi; Mario Bocchiardo; Francesco Urraro; Antonio De Simone; Roberto Ospizio; Antonio D'Onofrio
Journal:  J Interv Card Electrophysiol       Date:  2017-08-10       Impact factor: 1.900

2.  Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.

Authors:  Zhonglin Han; Zheng Chen; Rongfang Lan; Wencheng Di; Xiaohong Li; Hongsong Yu; Wenqing Ji; Xinlin Zhang; Biao Xu; Wei Xu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

3.  Contractility surrogates derived from three-dimensional lead motion analysis and prediction of acute haemodynamic response to CRT.

Authors:  Stian Ross; Hans Henrik Odland; Trent Fischer; Thor Edvardsen; Lars Ove Gammelsrud; Trine Fink Haland; Richard Cornelussen; Einar Hopp; Erik Kongsgaard
Journal:  Open Heart       Date:  2018-12-10

4.  Contrast-induced nephropathy after cardiac resynchronization therapy implant impairs the recovery of ejection fraction in responders.

Authors:  Teresa Strisciuglio; Giuseppe Ammirati; Valerio Pergola; Livio Imparato; Cristina Carella; Elisabeta Koci; Rosaria Chiappetti; Fabio Giovanni Abbate; Vincenzo Mirco La Fazia; Aniello Viggiano; Bruno Trimarco; Antonio Rapacciuolo
Journal:  ESC Heart Fail       Date:  2019-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.